A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01605396
Recruitment Status : Active, not recruiting
First Posted : May 24, 2012
Last Update Posted : January 5, 2018
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.